secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001093557-25-000029
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B
--------------------------------------------------------------------------

- Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.
- GAAP net income $151.7M ($0.38 diluted EPS) vs $256.3M ($0.62) YoY; non-GAAP EPS $0.45 vs $0.50.
- Full year 2024 revenue $4.033B (+11% YoY); GAAP operating margin 14.9% (-160bps); non-GAAP margin 18.8% (-100bps).
- Submitted G7 15-day CGM to FDA; secured Dexcom ONE+ reimbursement in France; partnership with ŌURA.
- FY2025 guidance: revenue $4.60B (+14% growth); non-GAAP gross margin ~64-65%; operating margin ~21%; Adj. EBITDA ~30%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000029/0001093557-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000029/dxcm-20250213.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer